



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

September 26, 2019

Christian S. Schade  
Chief Executive Officer  
Aprea Therapeutics, Inc.  
535 Boylston Street  
Boston, MA 02116

**Re: Aprea Therapeutics, Inc.  
Amendment No. 1 to Form S-1  
Exhibit No. 10.3  
Filed September 23, 2019  
File No. 333-233662**

Dear Mr. Schade:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance